|The genetics of Caenorhabditis elegans|
Genetics 77 (1), 71-94, 1974
|Circulating tumor cells, disease progression, and survival in metastatic breast cancer|
M Cristofanilli, GT Budd, MJ Ellis, A Stopeck, J Matera, MC Miller, ...
New England Journal of Medicine 351 (8), 781-791, 2004
|Circulating tumor cells: a novel prognostic factor for newly diagnosed metastatic breast cancer|
M Cristofanilli, DF Hayes, GT Budd, MJ Ellis, A Stopeck, JM Reuben, ...
Journal of clinical oncology 23 (7), 1420-1430, 2005
|Alpha interferon for induction of remission in hairy-cell leukemia|
JR Quesada, J Reuben, JT Manning, EM Hersh, JU Gutterman
New England Journal of Medicine 310 (1), 15-18, 1984
|Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma|
E Olsen, M Duvic, A Frankel, Y Kim, A Martin, E Vonderheid, B Jegasothy, ...
Journal of Clinical Oncology 19 (2), 376-388, 2001
|Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206|
A Ribas, LH Camacho, G Lopez-Berestein, D Pavlov, CA Bulanhagui, ...
J Clin Oncol 23 (896877.25), 2005
|Are the symptoms of cancer and cancer treatment due to a shared biologic mechanism? A cytokine‐immunologic model of cancer symptoms|
CS Cleeland, GJ Bennett, R Dantzer, PM Dougherty, AJ Dunn, CA Meyers, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
|Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study|
G Lopez-Berestein, V Fainstein, R Hopfer, K Mehta, MP Sullivan, ...
Journal of Infectious Diseases 151 (4), 704-710, 1985
|Lenalidomide induces complete and partial remissions in patients with relapsed and refractory chronic lymphocytic leukemia|
A Ferrajoli, BN Lee, EJ Schlette, SM O'Brien, H Gao, S Wen, WG Wierda, ...
Blood, The Journal of the American Society of Hematology 111 (11), 5291-5297, 2008
|Soluble TNF-α receptor 1 and IL-6 plasma levels in humans subjected to the sleep deprivation model of spaceflight|
WT Shearer, JM Reuben, JM Mullington, NJ Price, BN Lee, EOB Smith, ...
Journal of allergy and clinical immunology 107 (1), 165-170, 2001
|Nuclear factor–κB and STAT3 are constitutively active in CD138+ cells derived from multiple myeloma patients, and suppression of these transcription factors leads to apoptosis|
AC Bharti, S Shishodia, JM Reuben, D Weber, R Alexanian, ...
Blood 103 (8), 3175-3184, 2004
|Interleukin-6 and interleukin-10 levels in chronic lymphocytic leukemia: correlation with phenotypic characteristics and outcome|
L Fayad, MJ Keating, JM Reuben, S O'Brien, BN Lee, S Lerner, ...
Blood, The Journal of the American Society of Hematology 97 (1), 256-263, 2001
|Inflammatory response, immunosuppression, and cancer recurrence after perioperative blood transfusions|
JP Cata, H Wang, V Gottumukkala, J Reuben, DI Sessler
British journal of anaesthesia 110 (5), 690-701, 2013
|A cytokine-based neuroimmunologic mechanism of cancer-related symptoms|
BN Lee, R Dantzer, KE Langley, GJ Bennett, PM Dougherty, AJ Dunn, ...
Neuroimmunomodulation 11 (5), 279-292, 2004
|Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy|
L Pusztai, TR Mendoza, JM Reuben, MM Martinez, JS Willey, J Lara, ...
Cytokine 25 (3), 94-102, 2004
|Phase I Trial of a Ligand Fusion-Protein (DAB389IL-2) in Lymphomas Expressing the Receptor for Interkeukin-2|
CF LeMaistre, MN Saleh, TM Kuzel, F Foss, LC Platanias, G Schwartz, ...
Blood, The Journal of the American Society of Hematology 91 (2), 399-405, 1998
|Treatment of hairy cell leukemia with recombinant alpha-interferon|
JR Quesada, EM Hersh, J Manning, J Reuben, M Keating, E Schnipper, ...
|Comparison of assay methods for detection of circulating tumor cells in metastatic breast cancer: AdnaGen AdnaTest BreastCancer Select/Detect™ versus Veridex CellSearch™ system|
E Andreopoulou, LY Yang, KM Rangel, JM Reuben, L Hsu, ...
International journal of cancer 130 (7), 1590-1597, 2012
|Phase I trial of an interleukin-2 (IL-2) fusion toxin (DAB486IL-2) in hematologic malignancies expressing the IL-2 receptor|
CF LeMaistre, C Meneghetti, M Rosenblum, J Reuben, K Parker, J Shaw, ...
|Circulating tumor cells as prognostic and predictive markers in metastatic breast cancer patients receiving first-line systemic treatment|
M Giuliano, A Giordano, S Jackson, KR Hess, U De Giorgi, M Mego, ...
Breast Cancer Research 13 (3), R67, 2011